IMM 4.41% 32.5¢ immutep limited

orphan drug status, page-4

  1. 664 Posts.
    Looks like DCVax(R)-L could be a direct competitor to CVac.

    Any idea how much further down the research time-line Prima is with CVac?

    Northwestern Biotherapeutics also have many other tumour-specific vaccine therapies in trial that are using same technology. Will this leave Prima ultimately as a small antipodean also-ran?
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.